PHASE Scientific International Limited (PHASE Scientific) announced that the company has become the exclusive distributor in China for Liger Medical LLC (Liger Medical), a global leader in portable cervical treatment technologies, including thermal ablation and LEEP therapy.
Unlike traditional LEEP procedures, which involve irreversible tissue removal, Liger’s portable thermal ablation system offers a non-destructive, fertility-preserving alternative that enables treatment to take place in both primary care settings and advanced hospital day clinics. This innovation is particularly impactful when paired with PHASE Scientific’s urine-based HPV screening test, creating an integrated, end-to-end solution that supports the WHO’s “screen-and-treat” strategy for cervical cancer prevention.
“This partnership with Liger Medical reflects our commitment to bringing leading global innovation into China’s healthcare system,” said Dr Ricky Chiu, Founder and CEO of PHASE Scientific. “By integrating advanced treatment options into our cervical health portfolio, we are building a truly holistic ecosystem — one that empowers healthcare providers and improves access to preventive care for women across the country.”
The collaboration also highlights PHASE Scientific’s ability to create geographic synergy — connecting high-impact technologies from the U.S. with China’s growing need for scalable, accessible women’s health solutions.
"We have recognised a great need in China for a more portable, practical approach to cervical cancer screening and treatment technology. We are proud to partner with Phase Scientific, who can locally provide these breakthrough innovations in China,” said Dean Wallace, CEO of Liger Medical.
Through this exclusive partnership, PHASE Scientific strengthens its position as a leader in cervical health, offering a total solution that spans screening (HPV testing), diagnostics (AI-powered cytology), and treatment (thermal ablation and LEEP). The company remains committed to driving innovation that supports better outcomes, earlier intervention, and more equitable care for women in China and beyond.
